PathMaker Neurosystems Inc., a Boston (US) and Paris (France)-based clinical-stage neuromodulation company developing non-invasive systems for the treatment of patients with neuromotor disorders, received a grant of undisclosed amount.
Bpifrance provided the grant Through the Programme d’Investissements d’Avenir (PIA-1) program.
The company intends to use the funds for the development of its MyoRegulatorTM. collaborating with researchers and clinicians at the Brain and Spine Institute (Institut du Cerveau et de la Moelle Epinière – ICM) at the Pitié-Salpêtrière Hospital in Paris, which will be the site of the European clinical trial.
Led by Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer, PathMaker Neurosystems is a clinical-stage neuromodulation company developing non-invasive systems based on proprietary technology. It is advancing MyoRegulatorTM, a non-invasive neuromodulation device intended for the treatment of patients suffering from neuromotor spasticity.